AstraZeneca and GlaxoSmithKline have been given the go-ahead in Japan tomarket their respective orally-administered triptan antimigraine drugs Zomig (zolmitriptan) and Imigran (sumatriptan). The injectable version of Imigran was the first triptan to reach the Japanese market last year (Marketletter January 24, 2000).
Although the number of migraine sufferers in Japan is estimated at six-to-eight million people, there is little awareness of the condition, which is usually treated with conventional analgesics. Both companies are likely to have a difficult marketing job on their hands to raise the profile of the disease and build some momentum for their triptan products in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze